ondansetron has been researched along with Abnormalities, Drug-Induced in 18 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 9.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "To investigate whether ondansetron use during pregnancy is associated with increased rates of major or subgroups of malformations." | 9.01 | Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. ( Erol-Coskun, H; Kaplan, YC; Kennedy, D; Keskin-Arslan, E; Richardson, JL, 2019) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 8.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "To use data from two large studies of birth defects to describe time trends in ondansetron use for the treatment of first-trimester nausea and vomiting of pregnancy and to investigate associations, either previously reported or undescribed, between first-trimester ondansetron use and major birth defects." | 7.88 | Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. ( Anderka, M; Mitchell, AA; Parker, SE; Van Bennekom, C, 2018) |
| "Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied." | 7.79 | Ondansetron in pregnancy and risk of adverse fetal outcomes. ( Hviid, A; Pasternak, B; Svanström, H, 2013) |
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 5.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "To investigate whether ondansetron use during pregnancy is associated with increased rates of major or subgroups of malformations." | 5.01 | Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. ( Erol-Coskun, H; Kaplan, YC; Kennedy, D; Keskin-Arslan, E; Richardson, JL, 2019) |
| "To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum." | 4.93 | Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review. ( Carstairs, SD, 2016) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| "To use data from two large studies of birth defects to describe time trends in ondansetron use for the treatment of first-trimester nausea and vomiting of pregnancy and to investigate associations, either previously reported or undescribed, between first-trimester ondansetron use and major birth defects." | 3.88 | Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. ( Anderka, M; Mitchell, AA; Parker, SE; Van Bennekom, C, 2018) |
| "The potent hERG channel blocking drug ondansetron is used off-label for treatment of nausea and vomiting in early pregnancy." | 3.88 | Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade. ( Danielsson, B; Ritchie, HE; Webster, WS, 2018) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| "Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied." | 3.79 | Ondansetron in pregnancy and risk of adverse fetal outcomes. ( Hviid, A; Pasternak, B; Svanström, H, 2013) |
| " The experience with mitoxantrone (MIX) especially in the first trimenon is very limited, until now only one case of a pregnant woman with MS who was exposed to MIX in early pregnancy and delivered a growth restricted but healthy child was published." | 3.77 | A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. ( Chan, A; Epplen, J; Gold, R; Hellwig, K; Schimrigk, S, 2011) |
| "Ondansetron is a 5-HT₃ receptor antagonist that has been approved for the prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, and surgery." | 2.66 | Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. ( Andrade, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huybrechts, KF | 3 |
| Hernandez-Diaz, S | 4 |
| Straub, L | 2 |
| Gray, KJ | 2 |
| Zhu, Y | 2 |
| Mogun, H | 2 |
| Bateman, BT | 3 |
| Picot, C | 1 |
| Berard, A | 2 |
| Grenet, G | 1 |
| Ripoche, E | 1 |
| Cucherat, M | 1 |
| Cottin, J | 1 |
| Saban, A | 1 |
| Deruelle, P | 1 |
| Boisrame, T | 1 |
| Andrade, C | 1 |
| Sakran, R | 1 |
| Shechtman, S | 1 |
| Arnon, J | 1 |
| Diav-Citrin, O | 1 |
| Parker, SE | 1 |
| Van Bennekom, C | 1 |
| Anderka, M | 2 |
| Mitchell, AA | 2 |
| Danielsson, B | 2 |
| Webster, WS | 1 |
| Ritchie, HE | 1 |
| Balayla, J | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Kaplan, YC | 1 |
| Richardson, JL | 1 |
| Keskin-Arslan, E | 1 |
| Erol-Coskun, H | 1 |
| Kennedy, D | 1 |
| Kiernan, E | 1 |
| Jones, KL | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Pasternak, B | 1 |
| Svanström, H | 1 |
| Hviid, A | 1 |
| Wikner, BN | 1 |
| Källén, B | 1 |
| Carstairs, SD | 1 |
| Hellwig, K | 1 |
| Schimrigk, S | 1 |
| Chan, A | 1 |
| Epplen, J | 1 |
| Gold, R | 1 |
| Louik, C | 1 |
| Werler, MM | 1 |
| Rasmussen, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ondansetron and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Ondansetron; Preg | 2020 |
Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron.
Topics: Abnormalities, Drug-Induced; Administration, Intravenous; Administration, Oral; Antiemetics; Female; | 2020 |
Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antiemetics; Case-Control Studies; Cohort Studies; Female; Humans; Onda | 2019 |
Medications that Cause Fetal Anomalies and Possible Prevention Strategies.
Topics: Abnormalities, Drug-Induced; Acetaminophen; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Analg | 2019 |
Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; O | 2016 |
13 other studies available for ondansetron and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Ondansetron Use in Pregnancy and Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Intravenous; Antiemetics; Female; Humans; Ondansetron; | 2020 |
Ondansetron Use in Pregnancy and Congenital Malformations-Reply.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Ondansetron; Pregnancy | 2020 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Case-Control Studies; Drug Administration Schedule; | 2018 |
Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade.
Topics: Abnormalities, Drug-Induced; Animals; Antiemetics; Cardiovascular Abnormalities; Embryo, Mammalian; | 2018 |
Comment on: Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Humans; Ondansetron; Pregnancy | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Ondansetron in pregnancy and risk of adverse fetal outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antiemetics; Female; Fetus; Humans; Infan | 2013 |
Use of ondansetron during pregnancy and congenital malformations in the infant.
Topics: Abnormalities, Drug-Induced; Antiemetics; Female; Heart Septal Defects; Humans; Infant, Newborn; Mal | 2014 |
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Antineoplastic Agents; Female; Humans; Infant, Newb | 2011 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |